Related Experiment Video
Updated: Mar 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Erratum to: Reassessing the risk of natalizumab-associated PML
Joseph R Berger1,2, Robert J Fox3,4
1Multiple Sclerosis Division of the Department of Neurology, University of Pennsylvania, 3400 Spruce St., 3 W Gates, Philadelphia, PA, 19104, USA. joseph.berger@uphs.upenn.edu.
No abstract available in PubMed .
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
26:48Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Arboviral Encephalitis